- Home
- QNCX vs IKNA Comparison
QNCX vs IKNA Comparison
Compare QNCX & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- IKNA
- Stock Information
- Founded
- QNCX 2012
- IKNA 2016
- Country
- QNCX United States
- IKNA United States
- Employees
- QNCX N/A
- IKNA N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- QNCX Health Care
- IKNA Health Care
- Exchange
- QNCX Nasdaq
- IKNA Nasdaq
- Market Cap
- QNCX 44.0M
- IKNA 61.8M
- IPO Year
- QNCX 2019
- IKNA 2021
- Fundamental
- Price
- QNCX $1.03
- IKNA $1.08
- Analyst Decision
- QNCX Strong Buy
- IKNA Buy
- Analyst Count
- QNCX 5
- IKNA 2
- Target Price
- QNCX $8.00
- IKNA $3.00
- AVG Volume (30 Days)
- QNCX 511.8K
- IKNA 95.3K
- Earning Date
- QNCX 05-16-2025
- IKNA 05-20-2025
- Dividend Yield
- QNCX N/A
- IKNA N/A
- EPS Growth
- QNCX N/A
- IKNA N/A
- EPS
- QNCX N/A
- IKNA N/A
- Revenue
- QNCX N/A
- IKNA N/A
- Revenue This Year
- QNCX N/A
- IKNA N/A
- Revenue Next Year
- QNCX N/A
- IKNA N/A
- P/E Ratio
- QNCX N/A
- IKNA N/A
- Revenue Growth
- QNCX N/A
- IKNA N/A
- 52 Week Low
- QNCX $0.51
- IKNA $0.97
- 52 Week High
- QNCX $2.45
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- QNCX 38.67
- IKNA 37.62
- Support Level
- QNCX $0.98
- IKNA $1.22
- Resistance Level
- QNCX $1.16
- IKNA $1.29
- Average True Range (ATR)
- QNCX 0.09
- IKNA 0.09
- MACD
- QNCX 0.01
- IKNA -0.01
- Stochastic Oscillator
- QNCX 22.22
- IKNA 1.75
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.